Paper Details

  1. Home
  2. Paper Details

Impact of rituximab treatment on (90)Y-ibritumomab dosimetry for patients with non-Hodgkin lymphoma.

Author: ForeroAndres, KnoxSusan J, LobuglioAlbert F, MeredithRuby F, ShahJatin J, ShenSui, UsreyMarc E, WisemanGregory A

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This trial investigated the potential enhancement of (90)Y-ibritumomab therapy by a full course of rituximab followed by a single dose of (90)Y-ibritumomab.
Paper Details　
Original Abstract of the Article :
To determine whether the therapeutic effect of (90)Y-ibritumomab might be enhanced by a full course of rituximab followed by single dose of (90)Y-ibritumomab, the trial included pre- and post-rituximab treatment imaging with (111)In-ibritumomab and blood pharmacokinetics. Comparison of the pre- and ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.2967/jnumed.109.066597

データ提供：米国国立医学図書館（NLM）

Exploring the Synergy of Rituximab and (90)Y-ibritumomab

This research delves into the intricate world of cancer treatment, a vast and complex desert of possibilities. The study examines the potential synergy between rituximab and (90)Y-ibritumomab, two therapies used to treat non-Hodgkin lymphoma, a type of cancer that affects the lymphatic system. This research is like searching for a hidden spring in the desert – a combination of therapies that might unlock new avenues for effective cancer treatment.

Optimizing Cancer Treatment through Synergistic Therapies

The study investigates whether a full course of rituximab followed by a single dose of (90)Y-ibritumomab could enhance the therapeutic effect of (90)Y-ibritumomab in treating non-Hodgkin lymphoma. This is like discovering a new route through the desert, potentially leading to a more efficient and effective way to combat this disease. The research suggests that this combination therapy may be a promising approach for improving patient outcomes.

Navigating the Landscape of Cancer Treatment

This research highlights the ongoing quest for more effective cancer treatments, emphasizing the importance of exploring synergistic therapies. It's like navigating the desert with multiple tools – a combination of therapies may be more effective than using a single approach. By understanding the potential benefits of these therapies, we can better navigate the challenging landscape of cancer treatment.

Dr. Camel's Conclusion

This study delves into the potential synergistic effects of rituximab and (90)Y-ibritumomab in treating non-Hodgkin lymphoma. It suggests that a full course of rituximab followed by a single dose of (90)Y-ibritumomab could enhance the therapeutic effect, offering a promising avenue for improving patient outcomes. This research highlights the importance of exploring synergistic therapies in the complex desert of cancer treatment, potentially unlocking new paths towards better treatment options.

Date :
  1. Date Completed 2010-02-03
  2. Date Revised 2016-11-25
Further Info :

Pubmed ID

20008989

DOI: Digital Object Identifier

10.2967/jnumed.109.066597

Related Literature

Article Analysis
・Effects of ibritumomab injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.